Shares of clinical-stage biotech CRISPR Therapeutics(NASDAQ: CRSP)are down an eye-popping 12% as of 12:05 p.m. EDT Wednesday. The biotech's shares sank in response to a patient death in an early stage study assessing the company's off-the-shelf T-cell therapy, CTX110, in patients with CD19+ B-cell malignancies (blood cancers).
Will CRISPR stock continue to fall in 2022's trading?
CRISPR stock has continued to lose ground early in 2022's trading. The company's share price is down roughly 11% in January's trading so far. Even with the dramatic pullback across the last year of trading, CRISPR's stock is still up roughly 98% over the last three years.
What drove CRISPR Therapeutics'stock down 50% in 2021?
Shares of CRISPR Therapeutics ( CRSP 0.64% ) sank 50.5% in 2021, according to data from S&P Global Market Intelligence. After surging roughly 151% across 2020's trading, investors reassessed the gene-editing specialist's drug pipeline and moved out of the company's stock.
What is CRISPR Therapeutics working on?
CRISPR Therapeutics is also working with ViaCyte to engineer stem cells to potentially treat type 1 diabetes, with Vertex Pharmaceuticals on a range of additional programs spanning cystic fibrosis to Duchenne muscular dystrophy, and with Bayer on a range of programs in eye diseases, autoimmune disorders, and hemophilia.
Is Maxx chatsko stock a buy for CRISPR Therapeutics?
Maxx Chatsko has no position in any of the stocks mentioned. The Motley Fool owns shares of CRISPR Therapeutics. The Motley Fool recommends Vertex Pharmaceuticals. The Motley Fool has a disclosure policy.
Is Crispr stock a good investment?
Yes, CRISPR Therapeutics boasts explosive upside potential, but it also comes with a decent amount of risk, more so than many investors can handle.
What is happening with CRSP stock?
CRISPR Therapeutics (NASDAQ:CRSP) swells 19% this week, taking five-year gains to 377% We think all investors should try to buy and hold high quality multi-year winners.
Will CRSP stock go up?
Stock Price Forecast The 22 analysts offering 12-month price forecasts for CRISPR Therapeutics AG have a median target of 113.50, with a high estimate of 220.00 and a low estimate of 46.00. The median estimate represents a +75.56% increase from the last price of 64.65.
Is CRSP undervalued?
Valuation metrics show that CRISPR Therapeutics AG may be overvalued. Its Value Score of D indicates it would be a bad pick for value investors. The financial health and growth prospects of CRSP, demonstrate its potential to underperform the market.
Should I sell CRSP?
Out of 12 analysts, 4 (33.33%) are recommending CRSP as a Strong Buy, 4 (33.33%) are recommending CRSP as a Buy, 4 (33.33%) are recommending CRSP as a Hold, 0 (0%) are recommending CRSP as a Sell, and 0 (0%) are recommending CRSP as a Strong Sell.
Who owns CRISPR stock?
Top 10 Owners of CRISPR Therapeutics AGStockholderStakeShares ownedThe Vanguard Group, Inc.1.51%1,170,336T. Rowe Price Associates, Inc. (I...1.51%1,166,114Armistice Capital LLC1.32%1,024,000Bellevue Asset Management AG1.20%926,9056 more rows
What will CRSP stock be worth in 2025?
CRISPR Technologies: 191,416% implied sales growth by 2025 CRISPR Therapeutics (CRSP 7.83%), a company leaning on gene-editing technology to precisely alter genomic DNA and tackle hard-to-treat diseases, is expected to see sales climb from $719,000 in 2020 to a consensus of $1.377 billion by 2025.
Is Gene a good stock to buy?
Is Genetic Technologies stock a buy? According to analysts the answer is an unequivocal yes. The GENE price target from Wall Street is almost 10x higher than where the stock is currently trading. Clearly there is optimism about future pipeline successes.
Is Crispr stock overvalued?
Many CRISPR gene editing stocks have been overvalued, although share prices have dropped quite a bit.
What is the best biotech stock to invest?
8 best biotech stocks to buy in 2022:Alkermes PLC (ALKS)BioMarin Pharmaceutical Inc. (BMRN)CRISPR Therapeutics AG (CRSP)Exelixis Inc. (EXEL)Global Blood Therapeutics Inc. (GBT)Ionis Pharmaceuticals (IONS)Sarepta Therapeutics Inc. (SRPT)Vir Biotechnology Inc (VIR)
Is CRISPR Therapeutics overvalued?
To conclude, The stock of CRISPR Therapeutics AG (NAS:CRSP, 30-year Financials) is estimated to be significantly overvalued. The company's financial condition is fair and its profitability is poor. Its growth ranks in the bottom 10% of the companies in Biotechnology industry.
Key Points
Following some stellar gains, investors took a more cautious approach to CRISPR Therapeutics stock in 2021.
What happened
Shares of CRISPR Therapeutics ( NASDAQ:CRSP) sank 50.5% in 2021, according to data from S&P Global Market Intelligence. After surging roughly 151% across 2020's trading, investors reassessed the gene-editing specialist's drug pipeline and moved out of the company's stock.
So what
CRISPR Therapeutics' drug pipeline revolves around chimeric antigen receptor T-cells (CAR-T) that can be used to target malignant tumors.
Now what
CRISPR stock has continued to lose ground early in 2022's trading. The company's share price is down roughly 11% in January's trading so far.
Key Points
The market's waning appetite for growth-dependent stocks weighed on CRISPR Therapeutics last month.
NASDAQ: CRSP
You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
What happened
Shares of CRISPR Therapeutics ( CRSP 7.34% ) fell 10.4% in September, according to data from S&P Global Market Intelligence. There wasn't any business-specific news driving the sell-off, but the gene-editing company's stock got pinched as investors moved out of relatively speculative growth-dependent plays.
NASDAQ: CRSP
Rising Treasury bond yields, inflation concerns, and geopolitical tensions weighed on growth stocks last month. The Nasdaq Composite index ended the month down roughly 5.3%, and CRISPR Therapeutics was caught up in the sell-off.
So what
With bond yields and interest rates rising, some of the shine typically starts to come off of growth-dependent stock plays.
Now what
CRISPR Therapeutics stock has continued to slide early in October's trading. The stock is down roughly 8.9% in the month so far.
Premium Investing Services
Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.
What happened
Shares of CRISPR Therapeutics ( NASDAQ:CRSP) sank 12.5% in November, according to data from S&P Global Market Intelligence.
So what
CRISPR Therapeutics published its Q3 results on Nov. 3; it delivered a narrower-than-expected loss, but also sales that fell short of the market's expectations. The company posted a loss of $1.67 per share on revenue of roughly $820,000, while the average analyst estimate had called for a per-share loss of $1.75 on revenue of $1.3 million.
Now what
CRISPR Therapeutics stock has continued to fall in early December trading. The company's share price is down roughly 6.9% in the month so far:
What happened
Shares of CRISPR Therapeutics ( CRSP -4.33% ) are falling today, down by 9.7% as of 1:53 p.m. EST, after the company announced the pricing of a public stock offering. The gene-editing pioneer said it will offer up to 4.89 million shares at $64.50 apiece, which would generate gross proceeds of up to $315 million.
So what
CRISPR Therapeutics is exploring many applications for its gene-editing technology. For instance, CTX001 attempts to engineer cells in bone marrow such that the resulting red blood cells generated can function properly and relieve individuals suffering from sickle cell disease or beta thalassemia.
Now what
Even after taking today's tumble into account, shares of CRISPR Therapeutics are up 112% since the beginning of the year. Given a pipeline that is (or soon will be) buzzing with activity, it makes sense for the pharma stock to bolster its cash position.
Premium Investing Services
Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.
NASDAQ: CRSP
You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
What happened
Shares of CRISPR Therapeutics ( CRSP 5.35% ) lost 25.2% of their value in July, according to data from S&P Global Intelligence. The stock was at $161.22 when the market opened on July 1, and fell to $121.02 by the time it closed on Friday, July 30.
So what
There really wasn't any huge breaking news that hurt the stock, but it was at the tip of a trend away from high-valuation stocks with growth potential into value stocks throughout the month. The company, which works on gene-editing therapies, doesn't have any consistent revenue yet.
NASDAQ: CRSP
So far, the early trials for CTX001 seem to be proceeding well. On June 11, CRISPR and Vertex Pharmaceuticals ( VRTX -1.47% ) announced new data regarding 22 patients being treated with CTX001.
Now what
The biotech stock has climbed in August, mostly due to positive news coming out of the company's second-quarter report on July 29.
Premium Investing Services
Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.